Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients - Wikidata - wikimedia - TriplyDB

Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients

Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients

http://www.wikidata.org/entity/Q33381183

about

Eculizumab for dense deposit disease and C3 glomerulonephritis Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN Overview of C3 Glomerulopathy Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement Childhood-onset dense deposit disease: a rare cause of proteinuria C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.A case of regression of atypical dense deposit disease without C3 deposition in a child.Current concepts in C3 glomerulopathy.Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.Clinical features and outcomes of 98 children and adults with dense deposit disease.Eculizumab and recurrent C3 glomerulonephritis C3 glomerulonephritis associated with monoclonal gammopathy: a case series.Treatment options for C3 glomerulopathy Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association?Eculizumab in Pediatric Dense Deposit Disease.Dense deposit disease in Korean children: a multicenter clinicopathologic study.Post-infectious glomerulonephritis with crescents in adults: a retrospective study Revisiting post-infectious glomerulonephritis in the emerging era of C3 glomerulopathy Dense deposit disease and C3 glomerulopathy C3 glomerulopathy: clinicopathologic features and predictors of outcome.Dense deposit disease associated with monoclonal gammopathy of undetermined significance.American Society of Nephrology clinical pathological conference.C3 glomerulopathy: a new classification.Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.C3 glomerulonephritis and CFHR5 nephropathy.Recent insights into C3 glomerulopathy Histopathology of MPGN and C3 glomerulopathies.Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN Immunosuppressive Treatment in C3 Glomerulopathy: Is it Really Effective?Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.Retinal disease in the C3 glomerulopathies and the risk of impaired vision.Understanding the complement-mediated glomerular diseases: focus on membranoproliferative glomerulonephritis and C3 glomerulopathies.Staphylococcus Infection-Associated GN - Spectrum of IgA Staining and Prevalence of ANCA in a Single-Center Cohort.C3 glomerulopathy associated to multiple myeloma successfully treated by autologous stem cell transplant.C3 glomerulopathy.C3 glomerulopathy and current dilemmas.Novel factor H mutation associated with familial membranoproliferative glomerulonephritis type I.Pathology after eculizumab in dense deposit disease and C3 GN.C3 nephritic factor associated with C3 glomerulopathy in children.

P2860

Q24632330-4287CF9C-C5C9-40F4-96FE-8E313D0F60DB Q26741542-C2EBCB70-EED2-452D-B9AA-0F6E05A6E281 Q26747262-498FF76D-3251-45DD-8E7D-CA9E8AFDB33E Q33849695-445F40F7-9224-4D1E-B932-AC3AC2170E2A Q33906517-AA16C7AE-173A-451C-B2C5-28F62CBA76A3 Q34295006-01BF580A-6016-4CAC-AD67-E0AEF9D39D1F Q34417351-4C323842-641D-4BBA-80D8-91E4ED4C64B7 Q34574482-C2D35E5C-C32F-4A25-820E-4047220FC24D Q35246525-449AE677-4980-4778-9A5F-0DA6DF27C9A8 Q35580577-91D54FB7-CDC6-4F6E-8708-F8B1E9E63198 Q35597310-3EFB6961-FC9A-4895-9F7F-6A2C802B3F30 Q35618793-1951D633-3ED2-4DC7-AC60-AA0DD9B458D1 Q35624672-A7B37D5A-1E70-402A-97E4-B95E742593BA Q35983428-BE7F30A5-5EFE-4092-A810-DC3A32B1332D Q36123605-5E4F1846-8BED-4072-B684-184F3645CD04 Q36310131-4063346A-72FE-4204-B69D-A856871C9038 Q36689191-193AABD2-4740-49DD-A078-4DD3D3BC6607 Q36951249-6F094D52-1280-4994-AB14-AF9BDB3C3673 Q37286653-7A922C2C-ADF6-453C-A645-8C1E8E7816ED Q37426966-CF67A6D2-4652-4AA8-A1F1-ED39AABEEF1D Q37673264-D8EB55E2-71E9-4F00-A681-23742E784338 Q37682273-EAFE9A2F-78FC-40AC-85A9-DBCF6D268CC7 Q37770399-E490164F-1F81-4356-97BF-54D2F31C68E8 Q38048606-DBF12C0B-6445-4DF9-B622-73C5656D31E0 Q38057737-80B86109-D3A9-4EBF-A0E9-192EA927D80F Q38088187-83D6CCB1-DC67-40A4-9160-DF475151AC81 Q38275117-B773F9E5-154E-40E4-8105-6D4752F62937 Q38549182-FA9D7FB6-47A5-4478-8EB6-AF6F6B7DDCDA Q38633087-5D3AA7A3-754C-4079-9C6B-CEACA013EE37 Q38682243-FF955614-7BEC-4E36-9849-176B4AFE95A8 Q38749694-A576D503-14D2-4326-A3DC-2DD1B4C0E254 Q38749961-3EEC4B8B-676A-4043-94CE-886AE72DAC8D Q38880897-E7DF2B34-C7BF-4AB4-B69D-57AE165813F1 Q39002127-E96A02B0-1AEA-40D4-8123-FD8F63D5EFE1 Q39207517-55A9E1C2-AAE4-454A-B18F-FB1BA1917F82 Q39207807-C690D7EA-DB74-474C-ACB8-EF26CD162645 Q40439038-2616C442-DE4D-489C-B95A-52347AA37A2C Q40626473-EE10FC62-D304-48EB-9192-6A68981496BC Q42116082-B36B008C-8924-4F66-B287-3ACFCC389754 Q42246527-E88E7D7D-DA5D-4864-A9DE-60A7B356E5F5

P2860

Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients

http://www.wikidata.org/entity/Q33381183

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients

@ast

Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients

@en

type

label

Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients

@ast

Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients

@en

prefLabel

Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients

@ast

Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients

@en

P1433

Q33381183-468D3592-027D-440B-AA20-4949C71DE526

P1476

Q33381183-68DDD972-7D67-4B8B-BFD4-8316C024D3F5

P2093

Q33381183-7C3DC20F-BD09-4173-B2B5-B022813F45AD

Q33381183-7C5C0790-5E30-4D58-BC6C-69170FA69695

Q33381183-820D9DB5-93C1-4840-92B8-E9F5E5507985

Q33381183-AD035FA0-189F-4925-9E70-7E9A6A5A823C

Q33381183-BA1DC07B-A321-42CE-8145-E5A377F6C216

Q33381183-E625FD32-6041-4244-B454-62F03B5B3F5B

Q33381183-EC6FD5E6-49CC-4D5D-A786-B8A46F071B69

P2860

Q33381183-1D8EAD44-01D3-4940-A637-B8183CE6663D

Q33381183-2F32136A-EF58-4B00-B310-A08D5BB43CE3

Q33381183-503B3F7A-CE23-4FFD-AC0F-7F0C57FA492E

Q33381183-51BB34A5-97EB-4B86-A7D6-496AD02E5320

Q33381183-624BFDBA-1722-4AC7-8EAD-02D3FF65CF93

Q33381183-6DA88475-9035-4F63-AC26-844AD711B590

Q33381183-73777B68-5982-4024-BA05-220CA6F122EF

Q33381183-8D6B00DF-F92F-4A09-99F2-109BF0CBB80B

Q33381183-924B16FA-594B-4F82-A314-B74A887D2857

Q33381183-952C41E9-6786-43D5-94FD-4B200D4B0713

P304

Q33381183-2A87EBB9-996B-479C-BDC5-C8DC70E30286

P31

Q33381183-41B7B5D9-2991-4FB7-AEAE-0C3EB8F6ADA1

P356

Q33381183-5ECD4EE3-3800-4BB2-A4BF-45DB027C0DDD

P433

Q33381183-B3591D4F-6C47-4AA0-A772-2CBF55651B50

P478

Q33381183-1EF583FB-84AE-4D01-8022-28543F0BCC22

P50

Q33381183-20E334F2-FFEE-46B3-97DE-2483B1FF2B56

P577

Q33381183-654504BE-907E-4778-9B08-C10EB77A2B5D

P698

Q33381183-E04B2BCF-D6D0-44FA-8AFE-D305B44E9EF5

P932

Q33381183-8D37A97A-1728-4367-891B-CCD139B3CB98

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients

@en

P2093

Anthony M Valeri

http://www.w3.org/2001/XMLSchema#string

Gerald B Appel

http://www.w3.org/2001/XMLSchema#string

Glen S Markowitz

http://www.w3.org/2001/XMLSchema#string

Julius Sherwinter

http://www.w3.org/2001/XMLSchema#string

Samar M Said

http://www.w3.org/2001/XMLSchema#string

Samih H Nasr

http://www.w3.org/2001/XMLSchema#string

Vivette D D'Agati

http://www.w3.org/2001/XMLSchema#string

P2860

Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease)

Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H

Dense deposit disease: a variant of membranoproliferative glomerulonephritis

Mesangiocapillary glomerulonephritis: a long-term study of 40 cases

Dense deposit disease is not a membranoproliferative glomerulonephritis

Membranoproliferative glomerulonephritis type II (dense deposit disease): an update.

Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis.

Dense deposit disease: new insights.

New approaches to the treatment of dense deposit disease.

Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.

P304

22-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.03480708

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Michael B Stokes

P577

2008-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18971369

http://www.w3.org/2001/XMLSchema#string

P932

2615696

http://www.w3.org/2001/XMLSchema#string